TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study to Evaluate the Safety of Levemir® in Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age according to approved label in each country and physician discretion~* Type 1 or 2 diabetes~* Recently started treatment with insulin detemir at the discretion of the investigator. Before initiation of insulin detemir they should not have been treated with insulin~* Selection at the discretion of the physician~Exclusion Criteria:~* Current treatment with Levemir® (insulin detemir)~* Previously enrolled in the study~* Hypersensitivity to Levemir® (insulin detemir)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Type 1 diabetes (Type: None): Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
- Type 2 diabetes (Type: None): Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have confirmed B-CLL.~* Patients must have received at least one prior therapy and must require treatment for active disease~Exclusion Criteria:~* Treatment with any anti-cancer agents (chemotherapies, monoclonal antibodies, etc) within 4 weeks of start of study.~* History of significant allergic reaction to antibody therapies that required discontinuation of antibody therapy~* History of human immunodeficiency virus (HIV) positivity.~* Active infection requiring treatment~* Pregnancy or lactation~* Other severe, concurrent diseases or mental disorders~* Central nervous system involvement of chronic lymphocytic leukemia (CLL)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab plus Fludarabine (Type: EXPERIMENTAL): Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be documented to have Central Diabetes Insipidus (CDI) by at least two of the following four criteria (a-d):~  1. Failure to increase urine osmolality above 300 mOsm/kg during a period of fluid deprivation sufficient to raise plasma osmolality and sodium above the upper limit of normal level for the reference laboratory (usually 295 mOsm/kg and 148 mEq/l, respectively)~ 2. Complete and continuous control of the DI by desmopressin therapy without breakthrough diuresis, hypernatremia, hyponatremia, or symptoms or signs of water intoxication.~ 3. A deficient plasma vasopressin response to osmotic or non-osmotic stimulation.~ 4. Absence of the posterior pituitary bright spot on T-1 weighted midsagittal magnetic resonance imaging (MRI) of the brain.~* Given written informed consent prior to any trial-related procedure is performed~* 24 hour urine volume (mL), urine osmolality (mOsm/kg), urine specific gravity, and serum sodium (mEq/L) maintained at a normal level by desmopressin nasal administration~* Outpatient~* The participant is, in the investigator's opinion, otherwise healthy~* Be willing and able to comply with the protocol requirements including restriction of water intake~Exclusion Criteria:~* Presence or a history of nephrogenic diabetes insipidus or diabetes mellitus~* Presence of uncorrected hypothyroidism, hypoadrenalism or hypogonadism~* Abnormalities or disease of the oral cavity that might affect the release and absorption of drug~* Unable to be placed on water-intake restriction starting from two hours before bedtime~* Presence of a hypothalamus abnormality leading to thirst disorder~* Evidence of hepatic, renal, cardiac, or pulmonary dysfunction~* Uncontrolled hypertension~* Treatment with another investigational product within the past 3 months~* Concurrent treatment with diuretics, chlorpropamide, tricyclic antidepressants, indomethacin, carbamazepine~* Alcohol dependency or drug abuse~* Breastfeeding, pregnant, or likely to become pregnant~* A mental condition, the lack of decision-making ability, dementia or a speech handicap~* Any other reason that the Investigator believes inappropriate

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Desmopressin (Type: EXPERIMENTAL): Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has not taken common statins or ezetimibe within 6 weeks of study screening or patient is currently taking a daily dose of the following statins for 6 weeks prior to study screening: simvastatin, atorvastatin, pravastatin, fluvastatin, ezetimibe, lovastatin, or ezetimibe + fluvastatin~* Patient is willing to go on a cholesterol and glucose lowering diet for the duration of the study~* Patient is willing to remain abstinent or use birth control for the duration of the study~* Patient has Diabetes Mellitus with cardiovascular disease~Exclusion Criteria:~* Patient has sensitivity to certain common statin drugs~* Patient is Asian and would not be able to start taking the higher doses of rosuvastatin necessary for the study design~* Patient consumes more than 2 alcoholic drinks per day~* Patient is pregnant or breast-feeding~* Patient has been treated with other investigational drugs within 30 days of first visit~* Patient is currently on prohibited doses of the following statin drugs: rosuvastatin, simvastatin, atorvastatin, and pravastatin~* Patient has congestive heart failure~* Patient has uncontrolled high blood pressure~* Patient has kidney disease~* Patient has uncontrolled endocrine or metabolic disease which are known to possibly increase blood lipoproteins~* Patient has diabetes mellitus that is not well controlled~* Patient is human immunodeficiency virus (HIV) positive~* Patient is currently taking medications that inhibit Cytochrome P450 3A4 (CYP3A4)~* Patient is currently taking therapies that would increase the risk of muscle weakness~* Patient has been taking certain over- the-counter lipid-lowering agents within 6 weeks prior to visit 1~* Patient is currently taking psyllium or other fiber-based laxatives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe/simvastatin (Type: EXPERIMENTAL): None
- Doubling statin dose (Type: ACTIVE_COMPARATOR): None
- Rosuvastatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You must be suffering from symptoms of depression for at least the past 2 weeks (sadness, loss of interest in daily activities, feelings of hopelessness or guilt, sleeplessness or lack of energy)~* You must have pain symptoms with no known cause, such as unexplainable, head, chest, or back pain, overall aches and pains, or other unexplainable pains.~* You need to be available to visit a doctor's office about once a week for 10 weeks.~Exclusion Criteria:~* You are a woman and are pregnant or breastfeeding.~* You have a current or previous diagnosis of bipolar disorder, schizophrenia, or other psychotic disorder.~* You have had a primary diagnosis of an anxiety disorder within the past 6 months.~* You have a history of alcohol or drug dependence or abuse within the past 6 months.~* You have a serious medical illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiographic Progression of Sealed and Infiltrated Caries Lesions in Vivo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects were to have at least three caries proximal lesions on their posterior permanent teeth with a radiographic severity classification of the lesion score of 3 -Around the enamel dentin junction (EDJ) or 4 -Dentin-outer 1/3.~Exclusion Criteria:~* Under orthodontic treatment at enrollment~* Moving from the city (Bogota) in the following three years after commencing the study.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with Infiltrant/Adhesive (Type: EXPERIMENTAL): In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
- Placebo, placebo treatment (Type: PLACEBO_COMPARATOR): In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with a placebo treatment: At baseline one caries lesion was cleaned with a microbrush for 30 seconds and the procedure was repeated after two minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 65 years of age, inclusive, at the time of informed consent with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) for Schizophrenia and Psychotic Disorders Studies~* Would benefit from hospitalization or continued hospitalization for treatment of a current acute relapse of schizophrenia at trial entry~* Are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by all of the following:~* Positive and Negative Syndrome Scale (PANSS) Total Score of ≥ 80~* Score of ≥ 4 on two or more of the following PANSS items at screening: hallucinatory behavior, unusual thought content, conceptual disorganization, or suspiciousness~* Clinical Global Impression - Severity of Illness Scale (CGI-S) score ≥ 4 (moderately ill)~Exclusion Criteria:~* Are presenting with a first episode of schizophrenia based on the clinical judgment of the investigator~* Have been hospitalized \> 21 days for the current acute episode at the time of the baseline visit~* Have a current DSM-IV-TR Axis I diagnosis other than schizophrenia, including, but not limited to, schizoaffective disorder, major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, anxiety disorders, delirium, dementia, amnestic, or other cognitive disorders; also borderline, paranoid, histrionic, schizotypal, schizoid, antisocial personality disorders or mental retardation.~* Improvement of ≥ 20% in total PANSS score between the screening and baseline assessments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
- Aripiprazole (Type: EXPERIMENTAL): Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Marijuana for HIV-Related Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~* HIV positive.~* Be 18 years or older.~* Diagnosis of HIV-related painful neuropathy.~* Stable antiretroviral therapy or no antiretroviral therapy for at least 8 weeks.~* Prior use of marijuana, at least 6 occasions in their lifetime prior to enrollment.~EXCLUSION CRITERIA: (Not allowed)~* Current use of smoked tobacco products.~* Current methadone treatment.~* Use of smoked marijuana within 30 days of enrollment.~* Diagnosis of diabetes mellitus.~* Currently receiving treatment with corticosteroids.~* Use of INH, dapsone or metronidazole within 8 weeks prior to enrollment.~* Severe heart disease, uncontrolled high blood pressure or lung disease.~* Women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) of 18.0 to 31.0 kg/m2, inclusive, and a total body weight \>50 kg~* Diagnosis of small fiber neuropathy, as per European Federation Neurological Societies (EFNS)/American Academy of Neurology (AAN) guidelines, with pain for at least 3 months prior to screening~* Reduction below the 5th percentile of sex and age-adjusted normal values in epidermal nerve fiber density on punch skin biopsy at the distal site of the leg performed at screening~* Normal nerve conduction studies (NCS), including presence of sural response.~* Average NRS score between ≥4 and ≤9 reported in the daily diary on Days -7 through -1~Exclusion Criteria:~* History in the past 10 years of malignancy except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ~* History of connective tissue disorders, sarcoidosis, Sjögren's syndrome, amyloidosis, Fabry's disease, celiac disease, lyme disease, autoimmune disorders~* A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses~* Current clinically significant liver or kidney dysfunction~* Current uncontrolled thyroid dysfunction~* A diagnosis of diabetes, HbA1C ≥8% at screening~* History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)~* Concomitant severe pain conditions which may impair self-assessment of pain due to small fiber neuropathy~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- VX-150 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-IV-TR criteria for a primary diagnosis of ADHD~* Baseline ADHD-RS-IV score \>=28~* BP w/in 95th percentile for age, gender, and height~Exclusion Criteria:~* Subject has controlled or uncontrolled comorbid psychiatric diagnosis~* Subject has conduct disorder~* Suicidal~* Under or overweight~* Concurrent chronic or acute illness that might confound results.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lisdexamfetamine Dimesylate (LDX) 30 mg (Type: ACTIVE_COMPARATOR): None
- LDX 50 mg (Type: ACTIVE_COMPARATOR): None
- LDX 70 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females 18 to 60 years of age~2. Diagnosis of ADHD (any type: combined, predominately hyperactive impulsive type or predominately inattentive type) by a psychiatrist, psychologist, or licensed allied healthcare professional~3. Subject is willing and able to comply with all the protocol requirements.~Exclusion Criteria:~1. Primary and/or comorbid psychiatric diagnosis other than ADHD~2. Has a current or recent history of hypertension, symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug;~3. Has used any investigational drug within 30 days of the screening visit;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Active Treatment (Type: EXPERIMENTAL): PRC-063 25, 35, 45, 55, 70, 85, or 100 mg
- Placebo Treatment (Type: PLACEBO_COMPARATOR): Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Random Assignment of Intervention Messages for Developing Personalized Decision Rules to Promote Physical Activity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants capable of reading, speaking and understanding English and of giving informed consent.~* Participants between the ages of 18-29 years.~* Participants must be free of visual impairment that would interfere with the use of a smartphone.~* Participants must own and carry an iPhone (running iOS version 10 or higher) or Android (running operating system 7 or higher) smartphone during waking hours.~Exclusion Criteria:~* Participants engaging in 90 or more minutes of moderate- or greater intensity PA each week.~* Participants engaged in organized programs with mandated physical activity (e.g., varsity sports, ROTC).~* Participants with contraindications to normal physical activity on the Physical Activity Readiness Questionnaire.~* Participants who require an assistive device for mobility or have any other condition that may limit or prevent participation in moderate-intensity physical activity.~* Participants who are pregnant or planning to become pregnant within the next 6 months.~* Participants with a prior diagnosis of cancer, cardiovascular disease, diabetes or metabolic syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- Random Messaging (Type: EXPERIMENTAL): Participants receive 0-5 messages/day from the Random AIM app. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages are selected randomly from three content domains: Move More (40%), Sit Less (40%), and Inspirational Quotes Unrelated to Movement (20%). Half of the messages are accompanied by images. Message selection and timing are determined randomly each night for the following day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have smoked an average of at least 15 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.~Exclusion Criteria:~* Subjects with clinically significant cardiovascular disease in the past 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete